Among the 65 patients included in the pan-cancer analysis who were treated with BRAF inhibitors, MEK inhibitors, or a RAF inhibitor with available somatic mutation profiles from The Cancer Genome Atlas (TCGA), 30 were in the WW group, 22 were in the WM group, two were in the MW group, and 11 were in the MM group when we combined all partner genes derived from the previous GDSC data analysis (Fig. 4). Here, MAP2K7 is linked to cancer.